Clinical trials: Neoplasms, Oral
Adenocarcinoma of the Prostate
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
- Trial name
- DRibble (NCT02234921)
- Testing
- Cyclophosphamide, DRibble Vaccine, HPV Vaccinations
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UbiVac
Polycythemia Vera (SNOMED CT: 109992005)
Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera
This is a Phase 2 trial to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of oral epetraborole tablets for the treatment of adults with phlebotomy-dependent polycythemia vera (PV).
- Trial name
- NCT07891533
- Testing
- Epetraborole
- Where
- Australia
- Volunteers
- 75 people
- Sponsor
- AN2 Therapeutics, Inc
Cancer
Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GSK2118436 is an orally administered, potent and selective small molecule BRAF inhibitor that is currently being developed for the treatment of BRAF mutation-positive tumors.
- Trial name
- NCT01340833
- Testing
- GSK2118436
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Oral Squamous Cell Carcinoma
Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits.
- Trial name
- PRV111 (NCT03502148)
- Testing
- PRV111 (Cisplatin Transmucosal System)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Privo Technologies
Breast Cancer
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or…
- Trial name
- NCT06757335
- Testing
- HP568, HP568 in combination with palbociclib
- Volunteers
- 204 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Multiple Myeloma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in…
- Trial name
- NCT06896916
- Testing
- Etentamig, Iberdomide
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult…
- Trial name
- ESVECO (NCT05587049)
- Where
- 8 sites in Colombia
- Volunteers
- 70 people
- Sponsor
- AbbVie
Melanoma
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
This research study involves two investigational drugs, an Activator Ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001).
- Trial name
- NCT01397708
- Testing
- INXN-2001, INXN-1001
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alaunos Therapeutics
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Solid Tumours
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1…
- Trial name
- NCT01948297
- Testing
- Debio1347 (CH5183284)
- Where
- 8 sites in United States, Singapore and 3 more
- Volunteers
- 77 people
- Sponsor
- Debiopharm International SA
Advanced Solid Tumors
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours.
- Trial name
- NCT00782574
- Testing
- AZD2281, Cisplatin
- Where
- 3 sites in United States, Spain
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Multiple Myeloma, Autologous Stem Cell Transplant
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a…
- Trial name
- NCT02181413
- Testing
- Ixazomib Citrate
- Where
- 227 sites in United States, Argentina and 31 more
- Volunteers
- 656 people
- Sponsor
- Takeda
Solid Tumors (Phase 1), RAS Mutation
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations.
- Trial name
- NCT07252479
- Testing
- AN9025 oral capsule
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Breast Cancer
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
- Trial name
- CONTESSA TRIO (NCT03952325)
- Testing
- Tesetaxel, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Singapore and 1 more
- Volunteers
- 294 people
- Sponsor
- Odonate Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic…
- Trial name
- 453 Ph1 CLL (NCT06291220)
- Testing
- Obinutuzumab, ABBV-453
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Medical Oncology
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with…
- Trial name
- NCT02439346
- Testing
- BAY1143269 tablet
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Bayer
Mantle Cell Lymphoma (MCL)
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL) is a form of Non-Hodgkin Lymphoma (NHL - cancer of the lymphatic system in blood) where cells from outer edge of the lymph nodes, called mantle zone become cancerous.
- Trial name
- NCT04477486
- Testing
- Ibrutinib, Venetoclax
- Where
- 12 sites in Japan
- Volunteers
- 13 people
- Sponsor
- AbbVie
Colorectal Neoplasms
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral).
- Trial name
- NCT00101686
- Testing
- Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab
- Where
- 175 sites in United States, Australia and 2 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain…
- Trial name
- NCT07728188
- Testing
- Etentamig, Pomalidomide, Daratumumab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory…
- Trial name
- NCT01564537
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 24 sites in United States, Canada
- Volunteers
- 722 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.